ReviewInternational journal of molecular sciences2019
Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
213 citing papers in PubMed, 5 syntheses or guidelines pooled it, 377 citations in OpenAlex.
- Quercetin in Myocardial Ischemia-Reperfusion Injury: Mechanistic Evidence, Cardioprotective Effects, and Translational Challenges.Journal of biochemical and molecular toxicology · 2026Pooled it
- The role of machine perfusion in preventing recurrence after liver transplant for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Effects and Mechanisms of Fisetin against Ischemia-reperfusion Injuries: A Systematic Review.Current pharmaceutical biotechnology · 2024Pooled it
- Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Pooled it
- Cellular and Molecular Targets for Non-Invasive, Non-Pharmacological Therapeutic/Rehabilitative Interventions in Acute Ischemic Stroke.International journal of molecular sciences · 2022Pooled it
- Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction.BMC cardiovascular disorders · 2023Trial
- Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Effect of remote ischemic preconditioning among donors and recipients following pediatric liver transplantation: A randomized clinical trial.World journal of gastroenterology · 2021Trial
- Nitric oxide in the occurrence and development of ischemic cerebrovascular disease.Medical gas research · 2027Review
- Pathophysiology-guided biomarkers and therapeutics for precision trauma medicine in polytrauma with musculoskeletal injuries.Military Medical Research · 2026Review
- Article
- ROS-responsive carrier-free nanodrugs for three-pronged acute ischemic stroke therapy.Materials today. Bio · 2026Article
- Regional tissue perfusion index (RTPI): a new optical-based metric for quantifying regional tissue perfusion.Journal of clinical monitoring and computing · 2026Article
- MITF Regulates CFTR Expression to Participate in Myocardial Ischemia-Reperfusion Injury.The journal of gene medicine · 2026Article
- MSC-Derived Extracellular Vesicles Mitigate Ischemia-Induced Energetic Dysfunction During Ex Situ Perfusion of Rat Livers.Antioxidants (Basel, Switzerland) · 2026Article
- Anthocyanins as Adjunctive Dietary Modulators of the Gut-Eye Axis: Bioavailability, Biotransformation, and Implications for Ocular Health.Foods (Basel, Switzerland) · 2026Review
- Temporal changes of oxidative stress and ferroptosis-associated biomarkers in STEMI patients undergoing primary PCI and their correlation with myocardial reperfusion injury.BMC cardiovascular disorders · 2026Article
- MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury.Molecular biology reports · 2026Article
- The Impact of Normothermic Machine Liver Perfusion on Early Renal Outcomes After Simultaneous Liver-kidney Transplantation: A Propensity Score-Matched Analysis.Transplantation direct · 2026Article
- Glycitin Alleviates Myocardial Ischemia-reperfusion Injury By Suppressing Oxidative Stress and Apoptosis Through PI3K/Akt/NF-κB Pathway Modulation.Applied biochemistry and biotechnology · 2026Article
153 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia/reperfusion injury (IRI) permeates a variety of diseases and is a ubiquitous concern in every transplantation proceeding, from whole organs to modest grafts. Given its significance, efforts to evade the damaging effects of both ischemia and reperfusion are abundant in the literature and they consist of several strategies, such as applying pre-ischemic conditioning protocols, improving protection from preservation solutions, thus providing extended cold ischemia time and so on. In this review, we describe many of the latest pharmacological approaches that have been proven effective against IRI, while also revisiting well-established concepts and presenting recent pathophysiological findings in this ever-expanding field. A plethora of promising protocols has emerged in the last few years. They have been showing exciting results regarding protection against IRI by employing drugs that engage several strategies, such as modulating cell-surviving pathways, evading oxidative damage, physically protecting cell membrane integrity, and enhancing cell energetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.